Advanced Search
Contact | Corporate | Help

Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors

Sponsors:
  • Niiki Pharma Inc.
Phases:
  • Phase I
IndicationsAcronym:
  • Solid Tumors
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: NKP-1339
Enrollment:
50

Additional information about NCT01415297.


SourceSolution © 2008-2012